Inhibitor antibodies to factor VIII and factor IX: Management

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 2, 2000, Pages 179-188

  Lusher, Jeanne M ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

Anaphylaxis to factor IX; Autoantibodies to factor VIII; Factor IX inhibitors; Factor VIII inhibitors; Immune tolerance induction; Nephrotic syndrome; Porcine factor VIII; Prothrombin complex concentrates; rF VIIa

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANAPHYLAXIS; ANTIBODY TITER; BLEEDING; CROSS REACTION; DISEASE SEVERITY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW;

EID: 0033935277     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9821     Document Type: Review

References (69)

1. 1. Hay CRM, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate severity haemophilia A. Thromb Haemost 1998;79:762-766
2. 2. Schwaab R, Brackmann H-H, Meyer C, et al. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-1406
3. 3. Addiego JE, Kasper CK, Abildgaard CF, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993;342:462-464
4. 4. Lusher JM, Courter S, Spira J. Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B domain deleted F VIII (rVIII SQ). Haemophilia 1998;4:227. Abstract
5. 5. Hay CRM, Ollier W, Pepper L, et al. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997;77:234-237
6. 6. Oldenburg J, Picard JK, Schwaab R, et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors to factor VIII. Thromb Haemost 1997;77:238-242
7. 7. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thrombosis et Diathesis Haemorrhagica 1975;34:869-872
8. 8. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII inhibitors: Improved specificity and reliability. Thromb Haemost 1995;73: 247-251
9. 9. Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients. Blood 1994; 83:2428-2435
10. 10. Lusher JM, Arkin S, Abildgaard CF, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993;328:453-459
11. 11. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598
12. 12. Brackmann HH. Induced immunotolerance for factor VIII inhibitor patients. Prog Clin Biol Res 1984;150:181-195
13. 13. Aznar JA, Jorquera JL, Peiro A. Suppression of inhibitors in haemophilia with corticoids and factor VIII. Thromb Haemost 1983;49:241-243
14. 14. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia A and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988;328: 947-950
15. 15. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988;259:65-68
16. 16. Unuvar S, Warrier I, Lusher JM. Immune tolerance induction in the treatment of pediatric hemophilia A patients with factor VIII inhibitors. Haemophilia (in press)
17. 17. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992;14:82-87
18. 18. Mauser-Bunscholen EP, Nieuwenhius HK, Roosendaal G, van den Berg HM. Low dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995;86:983-988
19. 19. Kreuz W, Ehrenforth S, Funk M, et al. Immune tolerance therapy is paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995;1:24-32
20. 20. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia. Principal results from the International Registry. Thromb Haemost 1994;72:155-158
21. 21. DiMichele DM, Kroner BL, the ISTH Factor VIII/IX Subcommittee. Analysis of the North American Immune Tolerance Registry (NAITR) (1993-1997): Current practice implications. Blood 1997;90(suppl 1):156A. Abstract
22. 22. Lenk H. The German National immune tolerance registry - 1997 update. Vox Sang 1998
23. 23. Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993;70:56-59
24. 24. Nilsson IM, Berntorp E, Rickard KA. Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model. Haemophilia 1995;1:59-66
25. 25. Lusher JM, Blatt PM, Penner JA, et al. Autoplex vs. Proplex: A double controlled, double blind study of effectiveness in acute hemarthrosis in hemophiliacs with factor VIII. Blood 1983; 62:1135-1138
26. 26. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double blind clinical trial. N Engl J Med 1981;305:717-721
27. 27. Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991;28(suppl 6):3-4
28. 28. Chavin SI, Siegel DM, Rocco TA Jr, Olson JP. Acute myocardial infarction during management with an activated prothrombin complex concentrate in a person with factor VIII deficiency and factor VIII inhibitor. Am J Med 1988;85:245-249
29. 29. Kernoff PBA. Porcine factor VIII: Preparation and use in treatment of inhibitor patients. Prog Clin Biol Res 1984;150: 207-224
30. 30. Kernoff PBA. The clinical use of porcine factor VIII. In: Kasper CK, ed. Recent Advances in Hemophilia Care. New York: Liss; 1990:47-56
31. 31. Kernoff PBA, Thomas ND, Lilley PA, et al. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984;63:31-41
32. 32. Brettler DB, Forsberg AD, Levine PH, et al. The use of porcine factor VIII concentrate in the treatment of persons with inhibitor antibodies to factor VIII:C: A multicenter U.S. experience. Arch Intern Med 1989;149:1381-1385
33. 33. Lusher JM. Considerations for current and future management of haemophilia and its complications. Haemophilia 1995;1:2-10
34. 34. Martinowitz U, Schulman S. Continuous infusion of coagulation products. Int J Pediatr Hematol Oncol 1994;1:47-48
35. 35. Woloschik DMN, Rubinger M, Israels JJ, et al. In vitro stability of porcine factor VIII (Hyate:C®). Haemophilia 1997;3:21-23
36. 36. Hay CRM, Laurian Y, Verroust F, et al. Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine factor VIII by home therapy. Blood 1990;76: 882-886
37. 37. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983;71:1836-1841
38. 38. Lusher JM. Recombinant clotting factor concentrates. Baillieres Clin Haematol 1996;9:291-303
39. 39. Hedner U, Ingerslev J. Clinical use of recombinant F VIIa. Transfus Sci 1998;19:163-176
40. 40. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998;9;119-128
41. 41. Hoffman M, Monroe DM III, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998;9(suppl 1): S61-S65
42. 42. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in a patient with severe hemophilia A during synovectomy. Lancet 1988;2:1193
43. 43. Lindley C, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994;55:638-648
44. 44. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998;4:790-798
45. 45. Key N, Aledort LM, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918
46. 46. Shapiro A, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778
47. 47. Erhardtsen E, Nony P, Dechavanne M, et al. The effect of recombinant factor VIIa (NovoSeven™) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998;9:741-748
48. 48. Lusher JM. Acute hemarthroses - the benefits of early vs. late treatment with recombinant Factor VIIa. Semin Hematol in press
49. 49. Schulman S, d'Oiron R, Martinowitz U, et al. Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrinolysis 1998;8(suppl 1):S97-S101
50. 50. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995;94(suppl 1):49-52
51. 51. High KA. Factor IX: Molecular structure, epitopes and mutations associated with inhibitor formation. Adv Exp Med Biol 1995;386:79-86
52. 52. Giannelli F, Choo KH, Rees DJG, et al. Gene deletions in patients with haemophilia B and anti-Factor IX antibodies. Nature 1983;303:181-182
53. 53. Warrier I, Ewenstein B, Koerper M, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997;19:23-27
54. 54. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998;4:574-576
55. 55. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997;89:115-116
56. 56. Lenk H, Bierback U, Schille R. Inhibitor to F IX in haemophilia B and nephrotic syndrome in the course of immune tolerance treatment. Haemophilia 1996;2(suppl 1):104. (Abstract)
57. 57. Pollman H. A haemophilia B patient with complete factor IX gene deletion and a high titer antibody against F IX. Haemophilia 1996;2(suppl 1):72. Abstract
58. 58. Warrier I, Lusher JM. Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis 1998;9(suppl 1):S125-S128
59. 59. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981;45: 200-203
60. 60. Cohen A, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996;9:331-354
61. 61. Hausser I, Schneider B, Lechner K. Postpartum factor VIII inhibitors. Thromb Haemost 1995;73:1-5
62. 62. Kessler CM. An introduction to factor VIII inhibitors: Their detection and quantitation. Am J Med 1991;91(suppl 5A):1-5
63. 63. Ludlam CA, Morrison AE, Kessler CM. Treatment of acquired hemophilia. Semin Hematol 1994;31:16-69
64. 64. Macik BG. Treatment of factor VIII inhibitors: Products and strategies. Semin Thromb Hemost 1993;19:13-24
65. 65. Green D, Rademaker AW, Briet E. A prospective randomized trial of prednisone and eyclophosphamide in the treatment of patients with F VIII autoantibodies. Thromb Haemost 1993;70: 753-757
66. 66. Shaffer LG, Phillips. Successful treatment of high titer acquired factor VIII inhibitors in non-hemophiliacs with oral eyclophosphamide and prednisone. Blood 1995;86(suppl 1):191. Abstract
67. 67. Sultan Y, Maisonneuve P, Kazatchkine MD, et al. Anti idiotypic suppression of autoantibodies to factor VIII by high dose intravenous gamma globulin. Lancet 1984;2:765-781
68. 68. Schwartz RS, Begriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous immunoglobulin. Blood 1995;86: 797-804
69. 69. Pflieger G, Boda Z, Harsfalvi J, et al. Cyclosporine treatment of a woman with acquired haemophilia due to factor VIII:C inhibitor. Postgrad Med 1989;65:400-402